芬内伦和纽约心脏协会在心力衰竭中的功能类:FINEARTS-HF试验
John W Ostrominski1, Muthiah Vaduganathan1, Brian L Claggett1
1Cardiovascular Division, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, USA.
JACC. Heart failure
|April 15, 2025
概括
菲内伦有效地治疗心力衰竭 (HF),保持或轻微减少排气分数,无论NYHA功能类别如何. 这种药物在不同功能分类的HF患者中持续改善结果和患者报告的症状.
科学领域:
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
- 临床试验 临床试验
背景情况:
- 纽约心脏协会 (NYHA) 的功能分类是心力衰竭 (HF) 研究和临床实践中的一个关键指标.
- 了解不同NYHA类别的治疗效果对于个性化HF管理至关重要.
研究的目的:
- 为了评估费内伦在轻度减少或保留喷射分数 (HFmrEF/HFpEF) 的HF患者中的疗效.
- 为了确定费内伦的治疗效果是否根据患者的基线NYHA功能类 (II vs. III/IV) 变化.
主要方法:
- 预先对FINEARTS-HF试验数据进行了预先规定的分析.
- 对初级 (心血管死亡,HF事件) 和由NYHA类分层的二级终点 (II vs. III/IV) 进行了检查.
- 使用顺序逻辑回归评估NYHA函数类的变化.
主要成果:
- 费内伦始终降低了主要终点,无论NYHA功能类 (P相互作用 = 0.54).
- 与NYHAII类 (ARR:2.0) 相比,在NYHAIII/IV类患者中观察到更大的绝对益处 (ARR:4.5).
- 改善堪萨斯城心肌病问卷-总症状得分和安全概况在NYHA课程中是一致的.
结论:
- 芬瑞在减少临床结果和改善HFmrEF/HFpEF患者的健康状况方面表现出一致的有效性.
- 无论基线的NYHA功能类别,都观察到治疗的益处,在更有症状的患者中,绝对收益更大.
- 菲内伦为广泛的HF患者提供安全有效的治疗选择.
相关概念视频
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
321
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
321
01:17Pathophysiology of Heart Failure
1.4K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.4K
01:22Heart Failure Drugs: Diuretics
294
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
294
01:22Heart Failure Drugs: β-Blockers
278
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
278
01:26Heart Failure Drugs: Inotropic Agents
424
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
424
01:11Renal Failure: Dose Adjustments
37
In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
37